Therapy Areas: Inflammatory Diseases
BioPharmX Corporation elects David S. Tierney, MD as CEO
13 September 2018 -

Pharmaceutical company BioPharmX Corporation (NYSE American:BPMX) revealed on Wednesday the appointment of David S. Tierney, M.D., as its chief executive officer as well as a director of its board of directors.

Anja Krammer continues to serve as president and corporate secretary for the company.

Most recently, Dr Tierney has served as president and CEO of Icon Bioscience, where he led a team that in 2018 received US FDA approval of its New Drug Application (NDA) for DEXYCU (dexamethasone intraocular suspension), a dropless, long-acting therapeutic for treating inflammation associated with cataract surgery.

Previously, Dr Tierney was employed as president and chief operating officer of Oceana Therapeutics, Inc, president & CEO of Hydro Med Sciences (HMS), which emerged as Valera Pharmaceuticals, a fully integrated, commercial, specialty pharma company, as well as president of Biovail Technologies, a drug division of Biovail Corporation.

At the start of his career, Dr Tierney was a senior vice president of drug development at Roberts Pharmaceutical as well as part of Elan Corporation.

Login
Username:

Password: